Verastem, Inc. (NASDAQ:VSTM) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET
Company Participants
Daniel Calkins – Chief Financial Officer
Daniel W. Paterson – President, CEO & Director
Julissa Viana – Vice President of Corporate Communications & Investor Relations
Matthew E. Ros – Chief Operating Officer
Michael Crowther – Chief Commercial & Strategy Officer
Conference Call Participants
Anish Nikhanj – RBC Capital Markets, Research
Anqi Yu – Jefferies LLC, Research Division
Graig C. Suvannavejh – Mizuho Securities USA LLC, Research Division
Justin Reid Zelin – BTIG, LLC, Research Division
Michael Werner Schmidt – Guggenheim Securities, LLC, Research Division
Paul Jeng – Guggenheim Securities, LLC, Research Division
Pete George Stavropoulos – Cantor Fitzgerald & Co., Research Division
Sean Lee – H.C. Wainwright & Co, LLC, Research Division
Operator
Thank you for standing by. My name is Rebecca, and I will be your conference operator today. At this time, I would like to welcome everyone to the Verastem Oncology Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Thank you. I will now turn the call over to Julissa Viana, Vice President, Corporate Communications, Investor Relations Patient Advocacy. Please go ahead.
Julissa Viana
Thank you, operator. Welcome, everyone, and thank you for joining us today to discuss Verastem’s second quarter 2025 financial results and recent business updates. Earlier today, we issued a press release detailing our financial results for the second quarter of 2025. This release, along with a slide presentation that we will reference during our call today are available on our website.
Before we begin, I would like to remind you that any statements made during this call are not historical and are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these
#Verastem #VSTM #Earnings #Call #Transcript